ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

from BioSpace · host BioSpace

In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We'll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuests⁠Indu Navar⁠, CEO and Founder, EverythingALSDr. Olga Uspenskaya, Chief Medical Officer, VectorY TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Episode metadata supplied by the publisher feed · Published Feb 26, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

0:00 20:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 20 minutes long.

When was this BioSpace episode published?

This episode was published on February 26, 2026.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!